Workshop on acceleration of the validation and regulatory acceptance of alternative methods and implementation of testing strategies


Published in:
Toxicology in Vitro

Link to article, DOI:
10.1016/j.tiv.2018.02.018

Publication date:
2018

Document Version
Peer reviewed version

Link back to DTU Orbit

Citation (APA):
Workshop on acceleration of the validation and regulatory acceptance of alternative methods and implementation of testing strategies


PII: S0887-2333(18)30065-1
Reference: TIV 4242
To appear in: Toxicology in Vitro
Received date: 8 November 2017
Revised date: 28 February 2018
Accepted date: 28 February 2018

Please cite this article as: A.H. Piersma, T. Burgdorf, K. Louekari, B. Desprez, R. Taalman, R. Landsiedel, J. Barroso, V. Rogiers, C. Eskes, M. Oelgeschläger, M. Whelan, A. Braeuning, A.M. Vinggaard, A. Kienhuis, J. van Benthem, J. Ezendam, Workshop on acceleration of the validation and regulatory acceptance of alternative methods and implementation of testing strategies. The address for the corresponding author was captured as affiliation for all authors. Please check if appropriate.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
Workshop on acceleration of the validation and regulatory acceptance of alternative methods and implementation of testing strategies

A.H. Piersma\textsuperscript{1,2}, T. Burgdorf\textsuperscript{3}, K. Louekari\textsuperscript{4}, B. Desprez\textsuperscript{5}, R. Taalman\textsuperscript{6}, R. Landsiedel\textsuperscript{6}, J. Barroso\textsuperscript{7}, V. Rogiers\textsuperscript{8}, C. Eskes\textsuperscript{9}, M. Oelgeschläger\textsuperscript{9}, M. Whelan\textsuperscript{7}, A. Braeuning\textsuperscript{7}, A.M. Vinggaard\textsuperscript{10}, A. Kienhuis\textsuperscript{3}, J. van Benthem\textsuperscript{3}, J. Ezendam\textsuperscript{1}

\textsuperscript{1} National Institute for Public Health and the Environment (RIVM), Center for Health Protection, Bilthoven, Netherlands
\textsuperscript{2} Institute for Risk Assessment Sciences, Utrecht University, Netherlands
\textsuperscript{3} Bundesamt für Risikobewertung, Berlin, Germany
\textsuperscript{4} European Chemicals Agency, Helsinki, Finland
\textsuperscript{5} Cosmetics Europe, Brussels, Belgium
\textsuperscript{6} BASF SE, Ludwigshafen, Germany
\textsuperscript{7} European Commission, Joint Research Centre (JRC), Ispra, Italy
\textsuperscript{8} Vrije Universiteit Brussel, Brussels, Belgium
\textsuperscript{9} SeCAM, Magliaso, Switzerland
\textsuperscript{10} National Food Institute, Technical University of Denmark, Kgs.Lyngby, Denmark

Corresponding Author:
Aldert H. Piersma,
RIVM, P.O.Box 1, 3720 BA Bilthoven, Netherlands,
Email aldert.piersma@rivm.nl,
Phone +31-30-274-2526
Abstract
Aldert Piersma (RIVM)

This report describes the proceedings of the BfR-RIVM workshop on validation of alternative methods which was held 23 and 24 March 2017 in Berlin, Germany. Stakeholders from governmental agencies, regulatory authorities, universities, industry and the OECD were invited to discuss current problems concerning the regulatory acceptance and implementation of alternative test methods and testing strategies, with the aim to develop feasible solutions. Classical validation of alternative methods usually involves one to one comparison with the gold standard animal study. This approach suffers from the reductionist nature of an alternative test as compared to the animal study as well as from the animal study being considered as the gold standard. Modern approaches combine individual alternatives into testing strategies, for which integrated and defined approaches are emerging at OECD. Furthermore, progress in mechanistic toxicology, e.g. through the adverse outcome pathway approach, and in computational systems toxicology allows integration of alternative test battery results into toxicity predictions that are more fine-tuned to the human situation. The road towards transition to a mechanistically-based human-focused hazard and risk assessment of chemicals requires an open mind towards stepping away from the animal study as the gold standard and defining human biologically based regulatory requirements for human hazard and risk assessment.
General Introduction
Tanja Burgdorf (BfR)

Current validation procedures assess the reliability and relevance of individual test methods. These procedures are essential to investigate the technical validity and transferability of a method and are important in the process of regulatory acceptance, e.g. as an Organisation for Economic Cooperation and Development (OECD) test guideline. However, the validation process, as described in the OECD Guidance document 34 (1), requires significant time and financial resources demanding for a target-oriented and efficient selection and evaluation process.

Non-animal toxicological methods (e.g. in vitro assays, in silico models, -omics data) become increasingly available. Single alternative test methods can generally not replace in vivo test methods due to the inherent biological complexity of adverse effects. Hence different test methods need to be combined into integrated or sequential testing strategies in order to allow reliable prediction of adverse effects in vivo (2). However, up to now, there is no overarching strategy how to assess the predictivity and reproducibility of testing strategies for a specific regulatory need. The absence of such a procedure is an important hurdle in the process towards regulatory acceptance and implementation of alternative methods. Particularly, in contrast to OECD test guidelines covering single test methods, testing strategies are not currently covered by the OECD Council Decision on Mutual Acceptance of Data (MAD).

In recent years the concept of Integrated Approaches on Testing and Assessment (IATA) evolved at the OECD level and combines different methodological approaches in an iterative manner. In 2014 an IATA for skin corrosion/irritation was published as a first example and an IATA for eye damage/irritation was published recently (3, 4). The concept of Adverse Outcome Pathways (AOPs) was developed to organize the current mechanistic understanding and toxicological data on different biological levels (5). AOPs can also represent a framework to develop non-animal alternatives to in vivo testing as it has been shown for the AOP on skin sensitization. This AOP triggered the development of key-event based predictive alternative methods and facilitated their regulatory acceptance following publication of the corresponding OECD test guidelines (6-10). AOP-based IATAs are increasingly discussed and OECD guidance has been developed accordingly (11-13). IATAs were intended to be flexible and always include a degree of expert judgement to meet specific regulatory needs. Some elements of an IATA, however, can be standardized and interpreted according to well-characterized and transparent prediction models. These so-called Defined Approaches that consist of a testing strategy and a fixed data interpretation procedure (DIP) are currently discussed as a future tool in chemical safety assessment. In a proof-of-concept study 12 different Defined Approaches (DA) for skin sensitization have been established and described according to OECD guidance (14). The rapid congruent progress in the development of AOPs and novel, innovative alternative methods will further increase the need to integrate information from multiple sources into testing strategies (or defined approaches). The question arises how these test strategies can be harmonized and standardized and if and how they can be integrated into legal frameworks such as the OECD test guidelines programme to be covered by the MAD principle and to achieve legal certainty which is a prerequisite for their regulatory applicability. Therefore, a discussion started how these new paradigms can be integrated in the safety assessment of chemicals (15, 16).

To foster this dialogue, the German Federal Institute for Risk Assessment (BfR) in cooperation with the Dutch National Institute for Public Health and the Environment (RIVM), organised a joint workshop on 23 and 24 March 2017 in Berlin. International experts from governmental agencies, regulatory authorities, universities, industry and the OECD were invited to discuss current problems concerning the regulatory acceptance and implementation of alternative test methods and testing strategies to develop feasible solutions.
In a series of introductory talks, drivers and barriers of the process of regulatory acceptance of test strategies were presented. Experts from RIVM, the European Chemicals Agency (ECHA), the EU Joint Research Center in Ispra, Italy (JRC), Scientific Committee on Consumer Safety (SCCS), Cosmetics Europe and BASF described their point of view which provided the basis for a focused discussion in breakout groups during which three main questions were addressed. The first group discussed how the quality of alternative methods, in particular as a part of a testing strategy, can be improved, including the question for criteria that need to be defined prior to validation of a single test to assess its added value and position in a test strategy. The second group considered the important question how the validation process can be accelerated. Not only the question how the transfer from test method development into validation can be promoted was discussed but also if new methods should always be validated as part of testing strategies. The third group addressed the questions how a testing strategy has to be designed and validated in such a way that it satisfies the regulatory needs and how testing strategies could be on equal footing with individual test guidelines.
Lecture summaries

Mechanistic and computational toxicology using ontologies, and their consequences for validation of animal-free methods
Aldert Piersma (RIVM)

Human risk of chemical exposures is classically assessed based on toxicity studies in experimental animals. This practice is showing its limitations. Animal studies are not the perfect predictor for human hazard and risk, and ethical issues around animal experimentation have increasingly challenged the current hazard and risk assessment practice. Both these issues have stimulated the development and application of animal-free alternative methods for chemical hazard and risk assessment. Such alternative methods can be fine-tuned to the human situation since they can be developed from biological materials of human origin and can provide mechanistic information that can help to better understand hazard as opposed to the black box system of studying adverse health effects in the intact animal. The validation of alternative methods has classically been done by one to one comparisons with the gold standard animal study based on a limited number of reference chemicals. Predictivity was limited by the reductionist nature of the alternative test as compared to the animal study, and lacked the comparison with the species of interest, which is man. This practice has hampered implementation of animal-free methods in regulatory hazard and risk assessment.

Mechanistic toxicology has received more and more attention since the publication of the US National Academy of Sciences report on Toxicity Testing in the 21st Century (17). OECD has adopted the Adverse Outcome Pathway (AOP) approach and defined Integrated Approaches to testing and Assessment (IATA), and Defined Approaches (7, 13, 14). AOPs have helped identify pathways from initiating events to adverse outcomes via key events in physiology. In order to understand toxicity at the level of the intact human, AOPs should be integrated to a network of pathways, in which key event relationships are described in quantitative terms. This allows the design of a systems toxicology computerized model that integrates all information and predicts toxicity at the apical level. Based on the model, critical key events that are rate-limiting for the occurrence of adverse effects can be identified. These key events can be monitored in dedicated molecular and cellular assays, including organ-on-a-chip methodologies. The outcomes of this testing battery can then be fed into the model to predict adverse health effects. The virtual embryo project at US EPA has successfully shown the feasibility of this approach for selected aspects of embryogenesis (18-20).

The information at the basis of a computational systems toxicology model can be collected and structured in an ontology. Ontologies offer the matrix for mapping subjects and their interrelationships, and can be applied to physiological parameters and their quantitative relationships. The ontology does not need to be comprehensive as to physiology, but should cover all relevant toxicity pathways, which likely represent a fraction of the physiological landscape. Current extensive knowledge about basic biology, chemistry as well as toxicology offers a wealth of data to populate the ontology. As an example, molecular mechanisms in developmental biology are rapidly being elucidated. Chemical structure information allows prediction of the developmental toxicity potential of chemicals (21). The extensive ToxCast database contains a plethora of information on the molecular and cellular effects of thousands of chemicals in hundreds of assays (22). The crux is in describing the toxicity pathway ontology to the level of detail necessary for reliable toxicity prediction. One important pathway in prenatal development is the retinoic acid homeostatic system, that is crucial for vertebrate embryogenesis (23). A preliminary AOP framework has been published, and several in vitro assays have shown regulation of the framework after chemical exposures, such as rat whole embryo culture, the zebrafish embryo test, and the mouse and human embryonic stem cell tests (24). The time is right for investing in the ontology approach, feeding into a computational systems toxicology approach fine-tuned to man, avoiding the detour of the animal experiment.
Given that the systems toxicology model needs to be fed by results from combinations of in vitro assays, this affects the way these assays should be validated. Biological domain, technical performance and chemical applicability domain remain important characteristics of individual tests. The biological domain can be validated by testing a limited number of known positive and negative exposures in the system. However, as to predictivity, an individual assay with a necessarily limited biological domain will by definition not be able to detect all toxicants. It is the predictive capacity of the combination of assays that matters for the reliability of the system as a whole. Therefore, rather than testing a series of chemicals, it is more worthwhile to assess whether the biological domain of the combination of tests sufficiently covers all toxicity pathways that need to be assessed. The current expansion of molecular and mechanistic toxicology, in silico methods based on chemical structure and properties, and in vitro animal-free methodologies pave the way for an integrated animal-free approach for dedicated human hazard and risk assessment of chemicals.

Development and regulatory approval of alternative methods
Kimmo Louekari (ECHA)

The European Regulation on Registration, Evaluation, Authorisation and Restriction of Chemicals (REACH) requires that the *in vivo* tests be only made as last resort. The European Chemicals Agency (ECHA) therefore actively contributes to the development of new guidelines and testing strategies in collaboration with OECD and the European Union Reference Laboratory for alternatives to animal testing (EURL-ECVAM). At present *in vitro* test methods and IATAs are available for all lower tier human health endpoints, i.e. skin and eye irritation, corrosion, and skin sensitization. Consequently, REACH information requirements and ECHA Guidance have been updated. The next goal is the development of alternatives for the “higher tier” studies, repeated dose toxicity studies as well as developmental and reproductive toxicity studies.

To examine whether development of alternative methods can be accelerated, the related processes in OECD and in ECHA were examined. Before these processes start, test methods need to be prioritised for validation. Steps related to validation take totally 3.5 - 8 years. The most time consuming part is the actual validation study. Some aspects of that are covered elsewhere in this article. EURL-ECVAM has introduced a novel step in this process: it has founded so-called PARERE network (Preliminary Assessment of REgulatory RElevance). PARERE consists of a group of regulators who give advice on the regulatory relevance of new test submissions and strategy documents. PARERE consultations aim to ensure that the test methods entering to validation are such that they will be used in a regulatory work. This implies that a test method is likely to provide reliable and predictive data being required under relevant European legislations, e.g. for industrial chemicals. Indeed one possibility to accelerate the targeted development of new alternative methods is that ECHA and other regulatory agencies proactively inform the scientific community and validation bodies of the needs for alternative test methods. That will enable efficient use of the limited resources of scientific validation.

Table 1 summarises the process of guideline development in OECD. Totally this takes usually 2 -5.5 years but the process may be longer, when there are scientific controversies or disagreement on the actual regulatory need of a new test guideline. Therefore, in case a test guideline development is prolonged, one OECD member country should actively propose solutions and agreeable compromises.
Table 1. Development of new test guidelines and Guidance Documents in OECD.

<table>
<thead>
<tr>
<th>Step description</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>Submission of a project proposal (SPSF) to OECD, mostly by OECD member countries (MCs).</td>
<td>1-2 months</td>
</tr>
<tr>
<td>OECD MCs comment on the SPSF. Comments on potential regulatory use and relevance are crucial.</td>
<td>1-2 months</td>
</tr>
<tr>
<td>OECD Working Group of the National Coordinators for the Test Guidelines Programme (WNT) approves or rejects the test guideline project.</td>
<td>1 week</td>
</tr>
<tr>
<td>Draft test guideline is prepared by an OECD expert group: e.g. sensitivity, specificity, domain, limitations, and method optimisation are addressed.</td>
<td>18 months-up to about 5 years</td>
</tr>
<tr>
<td>OECD MCs and EU Agencies comment on the draft TGs and Guidance Documents.</td>
<td>2-3 months</td>
</tr>
<tr>
<td>OECD WNT discusses the draft test guidelines, approves it or sends it back to the expert group.</td>
<td>1 week</td>
</tr>
</tbody>
</table>

In Table 2, the recognition and the first steps of regulatory use of the new test methods are described. This work usually takes 1.5-5 years. In these steps, ECHA and the European Commission have an active role in analysing and communicating the correct regulatory use of test guidelines. A test guideline or an alternative method is a useful regulatory tool when it: (1) produces such data on toxicity that correspond (at least partly) with a specific information requirement, (2) enables classification and labelling, (3) enables risk assessment, which requires that the test result provide quantitative dose descriptor, to be used in setting a DNEL (Derived No Effect Level), (4) can contribute to an IATA, i.e. that it covers certain parts of an adverse outcome pathway, with a validated in vitro or in vivo method. Successful validation, predictivity and biological relevance of the test methods are obvious prerequisites of the regulatory recognition of new test methods.
### Table 2. Recognition and start of the regulatory use of new test guidelines under REACH.

<table>
<thead>
<tr>
<th>Step description</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inclusion of the approved OECD TGs in EU Test Method Regulation, by Commission</td>
<td>1 year-10 years</td>
</tr>
<tr>
<td>(not absolutely necessary)</td>
<td></td>
</tr>
<tr>
<td>Inclusion of the new method in ECHA Guidance. ECHA Guidance is authoritative</td>
<td>1-2 years</td>
</tr>
<tr>
<td>in specifying the regulatory scope and limits of the use of new test guidelines.</td>
<td></td>
</tr>
<tr>
<td>Update of the ECHA test method web site or inclusion in case the TM endpoint was</td>
<td>1-3 months</td>
</tr>
<tr>
<td>not there</td>
<td></td>
</tr>
<tr>
<td>First cases dealt with in ECHAs Committees, MSCA and RAC</td>
<td>6 month-2 years</td>
</tr>
</tbody>
</table>

There are possibilities to accelerate the regulatory recognition and use of new test methods and alternative data. REACH Committees could deal the precedence case early and thereby communicate the acceptability of various types of new data. In fact only the discussion and decision making in REACH Committees will show in practice how the new tests can be used by the regulators, and Committee discussions could be seen as “a test of acceptability”. Secondly, ECHA could use different channels/media to efficiently inform the industry of the new methods and alternatives. In particular cases, ECHA could even “publish” validated test methods before OECD approval, to encourage their use.

**Testing Strategies in Modern Toxicology: A Journey From Validation To Regulatory Acceptance**

Bertrand Desprez and Rob Taalman (Cosmetics Europe)

Current validation processes are inherently complex and contain various sources of uncertainty. Most validation bodies have a stepwise workflow. Whilst this is scientifically justified, the multiplicity of these steps as well as related and repeated clarifications and sub-evaluations are occasions of potential misunderstandings between the submitter and evaluators. This may partly explain why the pace of the validation process is relatively slow. Complexity is well reflected in the example of the skin irritation and corrosion endpoint. Not less than 24 statements, documents or guidelines were published between 1998 and 2014 when an Integrated Approach for Testing and Assessment (IATA) was finally accepted in the regulatory arena. The OECD Guidance Document No. 34 defines 7 key steps (e.g., reproducibility, predictivity) of a modular approach that EURL ECVAM implements (1). This approach has many advantages, it is clear (target values), transparent (available to all), scientifically sound (good predictivity should be reproducible), and already demonstrated its usefulness. It may benefit from further refinement, for instance, by extending its applicability beyond individual methods to combined methods / testing strategies. Issuing formal statements would certainly provide clarity here.

The validation process has several sources of uncertainty, pertaining to scientific and legal issues, to individual versus combined methods, and to the gold standard animal data. From the scientific perspective, the use of single absolute target values does not reflect statistical reality. For instance, the simple use of confidence intervals, rather than target values of reproducibility or sensitivity, would be a step towards more probabilistic validations. A recent opinion of the External Scientific
Advisory Committee to ECVAM (ESAC) on the use of Performance Standards to evaluate test methods similar to validated reference methods, although limited to similar tests methods (so-called “me-too” tests), provides some indications on these types of approaches (25). That would reflect the inherent variability in assays to be included in testing strategies. Legal uncertainties remain as to which types of international agreements formally ratify the regulatory acceptance. Whilst legal clarity exists in OECD test guidelines on individual assays that are covered by Mutual Acceptance of Data (MAD), IATAs are so far described in guidance documents (GDs), and are thus not covered by MAD. Regarding combined tests, there is uncertainty on cut-off values in prediction models. Are cut-offs of individual tests still fit for purpose? Cut-offs when tests are combined should be adapted, but, to date, this is not appropriately covered in GDs. As to animal data as the gold standard, in topical toxicology, there are publications showing shortcomings of the traditional animal tests. The same weight given to occurrence of an eye effect irrespective of its frequency leads to unjustified classification in the most severe category. In skin sensitisation, the Local Lymph Node Assay (LLNA) used, as a reference for validation, does not have a perfect accuracy rate (26). The question of appropriate gold standards in validation of alternative approaches is of utmost importance.

As methods are progressively being combined in testing strategies, the question arises how this affects the validation process. Performance of combined tests can be much different from that of individual tests within the combination. For example two independent test methods with sensitivity/specificity of 60%/80 % and 75%/90%, respectively, would have an overall performance, in a top-down approach, of 90%/72% (figure 1). The overall sensitivity is increased in comparison to individual methods since a positive prediction has 2 occasions to occur (true positive with the first method OR false negative in the first method then caught up as true positive in the second one). In parallel, the overall specificity decreases in comparison to individual methods, since a negative prediction requires that the two methods provide both a negative prediction.

Whereas each test method may not be individually validated and accepted, their sensitivity in combination should be sufficient to be accepted by regulatory authorities, for predictions in the frame of safety evaluations of chemicals. Guidance needs to be developed. Easing the validation process of combined test methods requires to systematically address the uncertainties described above. This should happen at an early stage of the validation process, and covered in an additional module, expanding the existing modular approach. AOPs, IATAs, but also exposure and kinetic modelling (ADME) tools are gaining importance in novel safety assessment approaches. More governance is needed on how to achieve their mutual and harmonised acceptance, as opposed to the well-defined acceptance of individual methods in test guidelines. Pending key questions regarding mechanistically-related considerations and their acceptance include: (i) what is the amount of MIEs / KEs from a known AOP that a testing strategy should be covering?; (ii) how can we achieve further development and application of a network of AOPs or even mode of action-based ontologies?; (iii) how can one waive binary predictions in this context and allow for quantitative characterisation?

OECD and EURL ECVAM are good fora to address all the above topics. Current validation processes historically allowed the validation of individual alternative test methods. There is still room left for adapting the validation process to the 21st century risk assessment, and here are 5 ideas on how to do it: (1) establish clear timelines between all steps of the validation workflow; (2) find flexible ways, but still formal ones, to strengthen cooperation and discussion between test developers and validation bodies, along the process. Case studies can be used as mechanisms to bring all stakeholders together; (3) systematically include uncertainty considerations, sufficiently ahead of regulatory acceptance for candidate integrated approaches; (4) clarify how to achieve mutual acceptance of integrated approaches or test strategies, and whether individual validation of each test method forming these approaches can be waived; (5) reach consensus on the value of gold standards, since animal approaches as reference have been shown to be uncertain.
Alternative methods in the chemical industry: hurdles to regulatory use and 12 proposals to overcome them
Robert Landsiedel (BASF)

Alternative methods (and animal methods alike) have to fulfill certain requirements to be used in the chemical industry. Figure 2 is illustrating the main requisites and prerequisites, and Figure 3 gives an example of an administrative process for validation in the EU and adoption of an OECD test guideline. In the following, hurdles to achieve regulatory acceptance and eventually regulatory use of a new method are discussed. Most toxicological studies are a legal obligation. The REACH regulation (27) defines toxicological standard information requirements in order to facilitate risk assessment and classification and labelling (Classification, Labelling & Packaging, CLP; (28)). REACH Annex VII demands information on skin corrosion/irritation, eye damage/irritation, skin sensitization, mutagenicity and acute systemic toxicity for all substances with a production volume above one ton per annum. Often, the information requirements refer to an animal method or the regulation, like CLP, was designed with animal studies and the data they are providing in mind. Currently work is undergoing to re-design regulations, like the United Nations Globally Harmonized System (UN/GHS) or REACH/CLP, taking into account results of non-animal methods. The question arises if regulations according to adverse outcomes (“endpoints”) are the only option to enable risk assessments or if they could – at least in part – be replaced or amended by information on earlier key events and biokinetic information.

In any case, new methods to provide data on the underlying AOPs will be needed. For a global and straightforward regulatory acceptance of the results, methods need to be validated and accepted by regulatory authorities. In order to facilitate the regulatory use of a greater number of new methods addressing different key events (KE) of an AOP, the validation process and regulatory acceptance needs to be simplified and sped up. So far only few information requirements of REACH can be completely fulfilled by alternative methods (id est: skin- and eye irritation and mutagenicity; the skin sensitization hazard can be tested by alternative methods, but potency sub-classification still requires animal testing). Obviously, method development is still needed to address the majority of toxicological endpoints, which are currently addressed by animal methods. The validation and OECD TG adoption are started by application of the test method developer via its member country. There is little guidance or prioritization on which methods should be developed. This leaves the OECD waiting for methods (and it is a matter of chance to have fitting methods to address an AOP adequately) and it leaves the test developer with the risk of investing in a method which is ex post not prioritized in or even not at all admitted to the OECD Test Guideline (TG) program. Hence, testing strategies according to AOPs and the requested performance of the respective methods should be pre-defined and method development should be prioritized accordingly.

In the process of TG adoption, intellectual property restrictions and limitations of the supply of biological materials are deliberated. There have, however, been cases of missing technical equipment (e.g. the opacitometer used for the bovine corneal opacity and permeability test, OECD TG no. 437; (29)). Moreover, it is unclear, how many (proprietary) methods are desirable to provide the same information, e.g. there are currently two reconstructed tissue models to test for eye irritation properties (OECD TG 492), four different models for skin irritation and corrosion (OECD TG 431 and 439 (30, 31), and three variants of the local lymph node assay (OECD TG 429, 442A and B) (32-34) but also methods not adopted by OECD (35, 36). It seems obvious, that more than one proprietary method should be adopted in the respective TG in order to avoid monopolies but resources may be too scarce to adopt as many as one hundred methods. This would, however, put the developer of the hundredth method at a competitive disadvantage, and prior information on whether another method will still be considered, would have saved resources (and disappointments).
Once a new method has been validated and accepted by regulatory authorities, it is generally considered “good forever”. Methods may, however, turn out to be of less or actually very limited value after they have been used for a while, e.g. the setting of starting doses for acute oral toxicity testing by cytotoxicity testing in mouse fibroblasts was shown to be ineffective (37, 38). Therefore, a systematic review of the performance of existing methods is needed and validations need to be revised if appropriate.

A different example of this is the application of methods to test for skin irritation which were validated for pure chemical substances and mixtures but were of limited use when applied to agrochemical formulations (39). In contrast, reconstructed human cornea-like epithelium models seem to be applicable to assess the eye irritant potential of agrochemical formulations (40). However, applying differing regional classification systems (EU CLP, the United States Environmental Protection Agency (US EPA), The Brazilian Health Regulatory Agency (Anvisa)) to the in vivo data as a reference in the validation of in vitro tests can affect the performance of in vitro methods (36). This illustrates the difficulties imposed on test method developers faced with the need to maintain the validation status of in vitro methods, in line with diverse classification requirements (36). Curren explored how alternative methods could be used for testing eye irritation hazards of antimicrobial household cleaning products (41). More of such work is needed to adapt and validate alternative methods for testing formulations.

Using alternative methods, skin irritation and corrosion can be addressed by a combination of a skin corrosion and a skin irritation test (OECD TGs430, 431, 435 and 439) (56-59). More complex endpoints, like skin sensitization, would require at least two methods and a data interpretation procedure to combine the results into an overall conclusion on the hazard (42, 43). In general, IATAs are used to integrate different test methods and their results. While individual methods have been validated and are covered by OECD’s MAD, IATAs are not. There will, however, be no stand-alone alternative methods to address complex toxicological endpoints in the future, but rather comprehensive combinations (44-46). Hence, testing strategies should be validated and IATAs should be accepted in the regulatory arena just as existing animal methods currently are.

Validated and accepted methods and also their combination in testing strategies and IATAs have limited precision (just like any method). The systematic analysis and consideration of this has only recently started (26, 47-49) and should be extended to all existing and future methods. A test method’s precision should be reported in the method description and the resulting uncertainty of all testing results should be clearly described in the study reports. Regulators as well as test developers and users should discuss how precise a method should be for a given application and what level of uncertainty is acceptable. While it may be desirable to have unlimited resources to develop new methods and strategies to assess hazards and risks, it is not realistic. Rather, resources are limited and this has always been reflected, yet not in a systematic way. A systematic approach was recently presented by Gabbert and co-workers using the example of skin sensitization assessment (50-52). The “value of information” provided by a testing method should be used to prioritize and validate methods in the future (53).

From single methods to Defined Approaches: ensuring acceptance and use of non-animal approaches
Joao Barroso (JRC)

While the need to conduct animal testing varies around the world, there continues to be progress in terms of reducing, refining or even replacing, to the extent possible, the routine requirement for such studies in decision making processes. Non-animal toxicological methods (e.g. in vitro methods, in silico predictive models, -omics data) are becoming increasingly available and more relevant from
both a biological (i.e., the complexity and physiological significance of the test system) and a mechanistic perspective (in terms of the endpoints measured). In a few cases, in vitro test methods have been found, under certain circumstances, to be suitable stand-alone alternatives to animal testing. However, in the majority of cases, data generated with non-animal methods will have to be used in combination to achieve full replacement of in vivo testing for the safety assessment of chemicals, because they are not able on their own to cover the variety of endpoints and biological complexity that is usually found in animal tests.

Until recently, a clear international strategy for harmonising novel data integration approaches that rely on multiple information sources to predict a toxicological endpoint for use in regulatory decisions was missing. Since 2014, however, the OECD started publishing Guidance Documents (GDs) on Integrated Approaches to Testing and Assessment (IATA) for a few human toxicological endpoints, such as skin corrosion/irritation (3) and serious eye damage/eye irritation (54), to address this gap. IATA are pragmatic, science-based approaches that rely on an integrated analysis and weighting of relevant existing evidence, from multiple information sources such as physicochemical properties, non-testing methods (e.g., Quantitative Structure-Activity Relationships (QSARs), read-across) and testing methods (e.g., in vitro, in vivo), and guide the targeted generation of new information where required, to inform regulatory decisions on the hazard identification, hazard characterisation, classification and labelling and/or safety assessment of chemicals. IATA can therefore reduce the overall number of tests that need to be conducted and avoid or reduce animal testing by using in vivo methods only as a last resort within the strategy.

Another important concept recently put forward by the OECD in GD No. 255 (55) is the distinction between IATA and the so-called Defined Approaches (DA). A DA consists of a fixed data interpretation procedure (DIP) applied to data generated with a defined set of information sources. Information sources within DAs typically include in vitro methods, physicochemical properties and/or computational methods such as QSARs. The output of a DA can be used either on its own or together with other information sources within an IATA. A generic representation of IATA and its elements, including DAs, is shown in Figure 4. Whilst IATA are intended to be flexible (e.g., in the choice of information sources used) and involve a degree of expert judgment (e.g., in the weighting of the information used – IATA assessments are mostly based on weight of evidence), DAs are standardised both in relation to the set of information sources used and in the procedure applied to the data to derive predictions of toxicological effects (i.e., the DIP). The expectation is that (i) the regulatory requirements, (ii) the information sources used in a given chemical assessment, and (iii) the expert judgement applied to those assessments, may vary substantially among regulatory authorities. For this reason, without further prescriptiveness and harmonisation, IATA solutions do not easily lend themselves to MAD between authorities in different countries, and hence may lead to an increase in costs for industry and governments performing risk assessments and making classification and labelling decisions. The added value of DAs in this scenario is therefore to provide the necessary standardisation in the way information is combined to generate outputs comparable to standard in vivo Test Guidelines (TGs), which in turn could lead to further international harmonisation in the application of non-animal approaches in the decision-making process and facilitate their acceptance and use.

Skin Corrosion/irritation, serious eye damage/eye irritation and skin sensitisation are three areas that have benefited from the development of a considerable number of in vitro methods that have been adopted by the OECD, namely TGs 430, 431, 435 and 439 for skin corrosion/irritation (31, 56-58), TGs 437, 438, 460, 491 and 492 for serious eye damage/eye irritation (59-63), and TGs 442C, 442D and TG 442E for skin sensitisation (8, 64, 65). However, important differences can be observed between these three areas. None of these TGs are full replacement options to the current regulatory in vivo tests but, for skin corrosion/irritation, the TGs can all be used stand-alone and a combination of a skin corrosion test (corrosive vs not corrosive) with a skin irritation test (not classified vs
classified) offers a full replacement solution (not corrosive + classified = irritant). The risk of dis-
harmonisation/confusion with several suitable alternatives is limited in this case and therefore, the
IATA GD No. 203 on skin corrosion/irritation (66) guarantees international use and acceptance of in
vitro data and provides an equal footing between non-animal approaches and the in vivo method
described in TG 404 (67). The case of serious eye damage/eye irritation is slightly more complex. In
this case, TGs 437, 438, 460 and 491 provide the possibility to identify chemicals inducing serious eye
damage (Cat. 1) but no prediction can be made from all other test results due to considerable rates
of Cat. 1 false negatives. TGs 437, 438, 491 and 492 are able to identify chemicals not requiring
classification (No Cat.) but again no prediction can be made from all other test results, in this case
due to considerable rates of No Cat. false positives. Eye irritation (Cat. 2) can therefore only be
concluded from a weight-of-evidence assessment and consequently, the IATA does not provide
sufficient certainty on the acceptance of in vitro data when "No prediction can be made" results are
obtained with the TGs. The development and acceptance of DAs for serious eye damage/eye
irritation may be able to close this gap to achieve full replacement of the in vivo method described in
TG 405 (68).

Even more complex is the current situation in the area of skin sensitisation. Even though, in the
(near) future, some in vitro methods may alone be able to generate comparable information to the
Local Lymph Node assay (LLNA) described in TG 429 (69) on the skin sensitisation potential and
potency of chemicals and gain acceptance to be used as full-replacement alternatives, the currently
adopted methods, when used in isolation, are not able to generate such information. As stated in the
adopted in vitro TGs, the generated in vitro data should be "considered in the context of an IATA"
(i.e. in combination with complementary information) and therefore, the TGs alone do not guarantee
the use and acceptance of the in vitro methods. To add to this complex scenario, Annex VII to the
REACH Regulation was revised in 2016, making the use of in vitro methods for skin sensitisation
testing a standard information requirement and the primary choice over in vivo studies (EC, 2016). As
a mid-term solution, OECD GD No. 255 (55) was developed and published to provide a set of
principles for reporting DAs and templates for their documentation in order to facilitate their
assessment and acceptance by regulatory authorities around the world. And in parallel, DAs based on
the use of multiple non-animal information sources were developed and documented in Annex 1 to
OECD GD No. 256 on the reporting of Defined Approaches to testing and assessment for skin
sensitisation (70), using the templates described in OECD GD No. 255. Of note, some of these DAs
appear to have comparable or better performance than the LLNA in predicting skin sensitisation
responses in humans and some are even able to provide information useful for the purpose of skin
sensitisation potency sub-categorisation (71).

In October 2016, the International Cooperation of Alternative Test Methods (ICATM) organised an
international workshop on the regulatory applicability and acceptance of non-animal approaches to
skin sensitisation, which was hosted by the European Commission’s DG Joint Research Centre, to take
stock of the latest developments and discuss potential follow-up actions. The workshop was
attended by representatives from more than 20 regulatory authorities from the EU, USA, Canada,
Japan, S. Korea, Brazil and China. The objectives were: (1) To map the regulatory requirements for
skin sensitisation across jurisdictions and sectors; (2) To discuss the opportunities and potential
obstacles to uptake and acceptance of non-animal methods; (3) To discuss the evaluation and
acceptance processes associated with the use of DAs and IATA; (4) To discuss potential criteria for
the assessment of DAs to facilitate regulatory use, such as e.g., biological plausibility, mechanistic
coverage, accessible data interpretation procedures, performance against reference chemicals.

From the discussions it became clear that the certainty required by industry and regulatory
authorities on the relevance and international acceptance of the available DAs for skin sensitisation
to guarantee their deployment and use, may only be achieved if they attain the same level of global
acceptance as the standard in vivo method(s). In follow-up discussions, the ICATM partners agreed
that an alternative approach to skin sensitisation assessment that provides equivalent information to the LLNA should be given equivalent regulatory recognition and status. It was also agreed that DAs which combine multiple non-animal methods can be implemented with equivalent levels of prescriptiveness and reliability in comparison to the LLNA. On this basis, it was concluded that DAs which are shown to be scientifically valid and fit-for-purpose should be incorporated into an OECD TG, as this would enable "equal footing" between those DAs and the LLNA (i.e., it would allow for the replacement of a standard by another standard). A new project proposal was therefore submitted by the EU, USA and Canada to the OECD Test Guidelines Programme in November 2016, proposing the international assessment of DAs for skin sensitisation and the development of a Performance-Based Test Guideline (PBTG) for those DAs shown to be valid and to provide a level of information equal to the LLNA. The project was accepted by the Working Group of the National Coordinators for the Test Guidelines Programme (WNT) and is currently underway.

It is important for the future to find the right balance between flexibility and prescriptiveness to embrace new science while allowing for the practicalities of regulatory implementation. IATA facilitate international harmonisation while allowing enough flexibility to accommodate scientific developments. However, due to their flexible nature and the consequential enhanced need for expert judgment, it will be more challenging than for DA to have IATA covered by MAD, which requires that data generated in any OECD member country (and non-member adherent to MAD) in accordance with OECD TGs and the Principles of Good Laboratory Practice (GLP) are accepted in other member and adhering countries (see: http://www.oecd.org/env/ehs/mutualacceptanceofdatamad.htm). For this reason, IATA descriptions have so far been published in GDs, which may not provide enough certainty in some situations to guarantee use and acceptance of non-animal methods. The standardised nature of DAs, however, should permit their description in TGs, coverage by MAD and increased certainty of acceptance and use.

Strategic approach to animal-free testing for genotoxicity in case of cosmetic products
Vera Rogiers (SCCS)

Genotoxicity is a key endpoint in the hazard assessment of any chemical as damage to the genetic material might lead to detrimental effects on human health. To assess possible genotoxic actions of chemicals, thus also of cosmetic ingredients, regulatory bodies worldwide recommend, in a first tier, to apply a battery of in vitro tests. These tests need to cover the most important genotoxicity endpoints, i.e. mutagenicity, clastogenicity and aneugenicity, the latter being structural and numerical changes at the chromosome level. If needed, this is followed up by in vivo genotoxicity studies.

By the introduction of an animal testing and marketing ban in the European cosmetic legislation (Regulation 1223/2009/EC), the 3Rs principle (Refinement, Reduction, Replacement)- an important principle that was being gradually introduced into the EU legislation- became for cosmetics restricted to 1R. As a consequence, only validated in vitro tests, eventually backed-up by in chemico and in silico data, had to become the sole predictor of possible genotoxic properties of cosmetic compounds. Using the in vitro and in vivo genotoxicity data of cosmetic annex substances (colorants, preservatives, UV-filters and hair dyes), available in the different opinions of the Scientific Committee on Consumer Safety (SCCS) issued between 2000 and 2012, important discrepancies were noticed between the in vitro and in vivo results. Indeed, positive results found through the application of the in vitro 3-test battery could most often not be confirmed in vivo because of the high sensitivity and very low specificity of the test battery (72). Therefore, the 3-test battery was replaced by a 2-test
battery composed of an Ames test and an *in vitro* micronucleus test. But still, when one of these tests has a positive outcome, no *in vivo* follow up is allowed and the “positive” compound is lost for cosmetic purposes.

As a possible solution, it was proposed to carry out other *in vitro* tests such as a reconstructed skin micronucleus test or a 3D-based comet assay, both promising but still under development by the cosmetic industry. Also *in silico* test results and biokinetic data, but in particular molecular and/or mechanistic information, could be used in a Weight of Evidence approach to de-risk a misleading positive *in vitro* result. In that context the PhD research of Gamze Ates was presented in which a testing strategy was developed which integrates the current 2-test *in vitro* genotoxicity battery either with computational tools (73), reporter-based assays (74) or genomic fingerprinting (75) to de-risk a misleading positive *in vitro* genotoxicity test. The results can be summarized as follows: (i) By integrating a variety of *in silico* tools (SARpy, TOXTREE, CAESAR, Derek, T.E.S.T, IN SILICO BATTERY) a sensitivity of 53-87% and a specificity of 52-71% could be obtained; (ii) By integrating 2 reporter-based assays (ToxTracker and Vitotox) a sensitivity of 93% and specificity of 73% was found, which shows a better performance than using only an Ames test and an *in vitro* micronucleus test; (iii) The best results were obtained by integrating genomic fingerprinting, which was realized by developing a qPCR-array, based on an 84-gene fingerprint. The latter could be retrieved from gene expression analyses on whole genome microarrays, using the human HepaRG cell line as *in vitro* model. Testing the qPCR array with 12 known genotoxic and non-genotoxic compounds showed a sensitivity and specificity of 83%. Other genomic fingerprint data existing in this field use either human TK 6 cells or HepG2 cells, which have a more limited biotransformation capacity. Consequently, obtaining mechanistic/molecular information by using a dedicated qPCR array based upon human HepaRG cells exposed to the compound under consideration, is proposed as a strategic and pragmatic approach, which together with expert advice, seems to provide an improved way forward for cosmetic ingredients in case of misleading positive results when no *in vivo* testing is possible. Such mechanistic approaches add weight to the evidence.
Breakout discussion group summaries

Breakout group 1: How can the quality of alternative animal-free methods be improved?
Chantra Eskes (SeCAM) and Michael Oelgeschläger (BfR)

The breakout group addressed a number of key questions in relation to quality control of single methods and testing batteries. There was general agreement that in the future a comprehensive assessment of a single method prior or after validation will be less pertinent, since most likely testing strategies and DAs composed of combinations of test methods will be needed. Any test method used within a testing strategy or DA should always be robust and provide an added value with respect to (regional) availability or applicability. In addition, the method’s relevance should be evaluated in terms of its mechanistic added value and contribution to the final predictive capacity of a testing strategy. It was considered particularly important that the same set of chemicals are assessed in the various test methods forming a test strategy or DA that target an adverse effect, in order to facilitate the development of DIP. The problem of testing concentrations of chemicals to the limit of solubility was acknowledge but reliable exposure data that would allow the definition of a relevant upper concentration limit is scarce and, thus, more work needs to be done to address this issue. There are increasing numbers of methods available that have not undergone formal validation but might still be valuable for in vitro testing as part of DAs. For example, in case of high-throughput screening techniques, the following elements were found important to warrant acceptance of the data: use of a battery of internal controls and reference chemicals, the coverage of biologically plausible mechanisms, the evaluation of within-laboratory reproducibility and a thorough analysis of primary data in order to assess the plausibility of data interpretation.

In general, a broadening of the applicability domain of in vitro methods to mixtures was also identified as an important issue that needs to be addressed. Mechanistic-based in vitro approaches can work for mixtures, although for certain types of mixtures or formulations, single (and potentially unknown) components might interfere with the test system. However, it was acknowledged that the definition of mixtures is difficult to address as clear and harmonized definitions are hardly achievable. Similar problems exist in the area of pharmaceutical products where drug interactions are also difficult to predict. In any case, the applicability of a test method needs to be considered taking into account mechanistic aspects. Feedback from users on a regular basis (e.g., every 4-5 years) might help to develop a better understanding of the applicability of test methods for various types of mixtures as well as chemicals over time that could also be used to update and improve already existing test guidelines.

Altogether, it was agreed that a comprehensive description of the biological system is of utmost importance, since the relevance or predictivity of a method depends on its ability to mimic (human) physiological processes in vivo. Following this line, in vitro data should be compared with the human situation in terms of physiology and toxicological understanding rather than with experimental animal data. This approach obviously depends on sufficient knowledge of the molecular mechanism(s) mediating adverse effects and the development and use of AOP was considered helpful, although this will not always be possible. The use of human-based in vitro systems might allow a higher predictivity than the current animal models. However, to confirm this, one would need reliable human data, which is rarely available, and closer cooperation with clinicians and biomedical researches was proposed to address this issue. There was general agreement that compound potency and toxicokinetic aspects have to be considered and the further development of suitable (human) PBTK models that in combination with reverse dosimetry might facilitate quantitative in vitro-in vivo extrapolation (QIVIVE) were generally regarded of central importance. All these various aspects of method description and use depend on a clear definition of an acceptable level of uncertainty. A level of uncertainty should be defined for all components of a testing strategy and DA.
However, it also became clear that the way how ‘uncertainty’ of a given approach is determined is not defined yet and might relate to its applicability domain, species differences as well as the level of mechanistic coverage. The EFSA guideline on uncertainty was considered a good starting point and AOPs were considered as a useful tool to evaluate at least the level of confidence in a defined biological process.

Finally, the current description of requirements and general guidance to conduct in vitro methods under GLP might be insufficient to ensure that test methods that have already received regulatory acceptance, e.g. as OECD test guidelines, are performed appropriately. However, the current development of the Guidance document on Good In Vitro Method Practices (GIVIMP) might at least partially solve this problem. In addition, the usual quality control measures according to ISO 17025, including small ring trials with blinded compounds, allows to ensure laboratory proficiency. One problem that was identified is the lack of sufficient detail in OECD guidelines that always need to be complemented by SOPs but often also require additional guidance. In particular, critical steps in the procedure are not explicitly described, but would be helpful to both test method users and quality auditors. Thus, it was proposed to describe critical steps already in the respective test guidelines.

**Breakout group 2: “How can the validation process be accelerated?”**
Maurice Whelan (JRC) and Anne Kienhuis (RIVM)

This breakout group addressed acceleration of the validation process and discussed factors that need to change to increase efficiency and effectiveness of validation studies. The breakout group agreed that instead of investing in acceleration of the classical approach to validation (e.g. in vitro methods subject to ring-trials) the validation framework should be changed rigorously, which would require a paradigm shift in the regulatory landscape. It was acknowledged that this is complex and requires a long term investment.

A limiting aspect in the current approach to validation and acceptance of alternative methods that was discussed in the breakout group was the reference to the animal study as the gold standard. It was mentioned that it is sometimes perceived that regulatory agencies are reluctant to talk about the limitations of animal data. It is also experienced that more is asked for validation of alternative methods than for “gold standard” in vivo methods. A suggested solution may be the use of appropriate benchmarks that are compared to the human situation instead of using one-in-one comparison of alternatives with animal tests. It was addressed that, compared to in vivo studies, non-animal alternatives produce new types of data, which on the one hand means that some information may be lost but on the other hand, new information may be gained. To gain as much information as possible from non-animal alternatives, human relevant and mechanism-based testing strategies instead of individual methods or tools should be used. Since focusing on limitations restricts thinking, the break out group suggested focusing on what works, even if it results in accepting a certain level of uncertainty, which is already the case today when using the so-called “gold standard” in vivo methods.

It was observed that the validation in its current form is perceived as non-attractive, considering complexity, costs and time. A new validation framework should start with the establishment of the essential elements that are required in the new framework. These include biological relevance, transferability and reproducibility. With the new technologies evidence should be collected that is covering the biological domain. Furthermore, the methods need to be used by many people and should generate similar results. When transferability and reproducibility are not properly organized, it can affect trust in the system. Based on these principles, it can be discussed how new technologies, such as omics, can be considered in the regulatory framework. Otherwise, technologies that are originally developed to accelerate the process might instead decelerate progress. Furthermore,
validation can be made more attractive for scientists in academia. A suggestion was to change the term “validation” into “quality assurance” and to integrate the process in grant programs. Resources and finances are needed to keep evaluating and improving the new technological advancements. Next to the investment in advanced and complex technologies, it should be taken into account that there might be modest, low tech solutions as well.

In the current validation framework, the OECD is a democratic organization with a large number of test guidelines and projects on the work plan, working with diplomacy and consensus, and dealing with many stakeholders in the same strategic level playing field. This should be acknowledged since a rigorous change of this system may affect socioeconomic legal implications. Validated methods and OECD guidelines are a legal obligation to obtain H (hazard) sentences for CLP (Classification, Labeling and Packaging of chemical substances and mixtures). It was suggested in the breakout group to use the democracy represented by OECD in the current framework as a driver to accelerate the validation process. It is observed that within the big machinery of the OECD, new methods that are critically needed are validated quite fast. In these cases, there is a sense of intrinsic priority to get democracy in action. On the one hand, the framework needs a certain degree of prescription. On the other hand, the acceptance of new methods requires some flexibility within the framework.

In the concluding part of the group discussion, it was proposed that a global organization, a strategic vision, and an integrative approach are needed. Specifically, different stakeholders (academia, clinicians, toxicologists, regulators, industry) need to work closer as a team, already at the start of the development of a new fit for purpose method or strategy. Although conflicts of interest will exist, stakeholders should focus on common interests and decide what needs to be done. In the end, all stakeholders aim to provide the best, safe products on the market, when possible, avoiding using animals. Key to a successful validation framework is collaboration and communication which should be coordinated, fluent and easy. The break out group suggested that the efficient development, validation and acceptance of methods can be achieved by establishing a multi-stakeholder working group. Together, they can define common goals, identify hypothesis, address endpoints, select chemicals and assess quality of methods. These multi-stakeholder working groups can work on so-called case studies. It was concluded that these case studies could serve as the new validation (or ‘quality assurance’).

Breakout group 3: “How can regulatory animal-free approaches be facilitated?”
Jan van Benthem (RIVM) and Janine Ezendam (RIVM)

First, the group identified main issues that have an impact on regulatory acceptance and implementation of novel approaches. One is that regulators prefer methods that provide them with the same level of information and/or read-out as the current (animal) standard. Modern toxicology assays, however, may deliver different read-outs and in vitro assays do not always give a quantitative measure. Those assays that do provide dose-response data may be used to derive a no-effect level, but it is not yet fully understood how well those correlate with a DNEL or NO(A)EL which are essential to adequately perform a safety assessment. Quantitative in vitro – in vivo extrapolation (QIVIVE) modelling is evolving, which will lead to further understanding whether in vitro quantitative data can be used to derive an equivalent DNEL/NO(A)EL. Furthermore, the current paradigm does not allow easy introduction of innovative approaches that mostly measure mechanisms of toxicity rather than an apical endpoint. Clearly, a paradigm shift is needed to allow incorporation of novel non-animal approaches, although it was acknowledged that this is a far from simple task.

An important observation was that regulators have different roles and influence in the process of regulatory acceptance and implementation. Some regulators are involved early, whereas others become involved at the end of the process or not at all. Lack of familiarity with novel approaches can
make a regulator reluctant to approve its implementation. Some regulators are already involved in
the early evaluation of the regulatory relevance of a new method (e.g. EURL ECVAM’s PARERE
network) or at the OECD level in the test guideline program. Many regulators are only performing
dossier evaluations, often with time constraints. They have insufficient time to become acquainted
with novel non-animal approaches and keep pace with the scientific progress made in this area. For
these reasons, they will be cautious to use these new approaches. In addition, test method
developers often have insufficient insight into the needs and thoughts of regulators. These
observations indicate the need to encourage and improve interactions between test developers and
regulators / risk assessors. Also, due to the different vertical legislations for chemical safety there are
multiple enforcement bodies that play different roles in the process towards regulatory acceptance
and implementation. Hence, there is an urgent need for harmonization and to share best practices
and experiences to facilitate regulatory acceptance of novel methods in all relevant regulations. Early
involvement of regulators in the process of development of new methods is therefore considered of
importance, but may be challenging. Experience from EURL ECVAM with their PARERE network
shows that often regulators find it difficult to evaluate upfront whether a method that is not yet
validated is fit-for-regulatory purposes.

Another factor that was considered to hamper the implementation of 3R approaches was the United
Nations Globally Harmonized System of Classification and Labelling of Chemicals (GHS) (76) and the
European Union Regulation on Classification, Labelling and Packaging of chemicals (CLP)
implementing UN GHS in EU (77). GHS/CLP is an important system to inform users about chemical
hazards through the use of standard symbols and terms. Information on hazards is obtained
according to GHS/CLP criteria, which in its current form does not allow the use of in vitro data. Since
CLP criteria are important in several downstream regulations, some discussants considered this an
important hurdle in the acceptance of non-animal approaches. Hence, targeted actions to modify
these criteria are essential to ensure a broader use of the validated and relevant non-animal
methods. One important initiative is undertaken by the Netherlands, trying to adapt the GHS criteria
allowing the use of in vitro data to assess skin corrosion/irritation properties.

The group discussed as the third point the choice of the benchmark ('gold standard') used to
compare the predictivity of the new method or testing strategy. Traditionally data from animal tests
are used as a benchmark, but the concern was expressed that uncertainties and variability of these
reference data are not fully understood nor are they currently being considered during the process of
validation and acceptance of alternative approaches. Another drawback of the sole reliance on
animal reference data is that for many “novel” human-relevant toxicological endpoints no or limited
animal data are available, e.g: developmental neurotoxicity and endocrine disruption. Clearly, there
is a need for another benchmark that informs on the mechanistic relevance for a specific endpoint.
Understanding of human biology or a clear mechanistic description of a toxicological endpoint in an
AOP or MoA was considered essential for this purpose.

The fourth topic on the optimal way to design and validate a testing strategy in such a way that it
satisfies regulatory requirements or needs was also shortly discussed. No solutions or
recommendations were made during this workshop, but some valid points were raised. The modular
approach used for an individual test method (78) is applicable to testing strategies as well, although
the relative importance of the different modules and the order under which they should be
addressed may need to be different when moving from the validation of individual methods to
validation of testing strategies or of batteries of tests. Regulators prefer a DA that consists of a
predefined number of assays, a fixed prediction model and a clear-cut outcome, over an IATA. An
IATA offers more flexibility in selection of the methods performed for a specific chemical and the
decision is based on a weight-of-evidence approach, leaving more room for subjective interpretation.
From a scientific perspective IATA has many advantages, because it can be a targeted chemical-
specific approach that allows selection of the most appropriate methods and incorporation of novel
methods when they become available. From the perspective of a regulator, however, IATA may be more difficult to accept, because of the flexibility in both test method selection as well as data interpretation.

The last topic discussed in this group was how DAs and eventually also non-animal IATA solutions can be on equal footing with individual in vivo test guidelines, for which MAD applies. It was anticipated by the group that it would be easier to develop a test guideline for a DA, than for an IATA. More clear guidance is needed on how to perform a weight-of-evidence approach in order to standardise IATA-based assessments to a level permitting MAD. The downside is that once novel individual assays become available, it will be difficult to adapt the DA. The scope, limitations and uncertainties of the DA need to be clearly defined. Furthermore, an easy prediction model or DIP is preferred by regulators.

In summary, Europe needs a taskforce that coordinates knowledge and data sharing between different international regulatory bodies and EU member states to enable harmonized use of novel non-animal approaches. It is important to characterize upfront what the method is fit for and be clear and transparent about its limitations. Communication between different stakeholders (academia, regulators, industry) should be improved and we should invest in clear terminology and guidance.
Outlook
Aldert Piersma (RIVM)

After decades of dedicated research into animal-free methods for chemical hazard and risk assessment, we are still pondering the question of how validation, acceptance and regulatory implementation of these methods can be accelerated. We do note that much important work has been done on the development of alternative methods. Many in vitro methods are proving useful at least in a screening environment, e.g. to provide first indications of compound effects and for prioritization purposes among chemical analogs. However, replacement of animal studies in regulatory settings has been very scarce. This stagnation was mainly caused by the use of the animal study as the gold standard for human hazard assessment, and the consequential procedure to validate an alternative assay one to one against the animal study data. The reductionist nature of in vitro alternatives in most cases limits their individual validity for predicting toxicity in the intact organism. In addition, superficial in vitro to in vivo comparisons have reduced the impact of validation studies, such as scoring compounds as positive or negative, whereas it is the potency that determines toxicity.

The present workshop has pointed out that the classical bottom-up development and validation of alternatives for regulatory toxicology has to be balanced by a top-down approach from the perspective of regulatory needs based on scientific knowledge. Moreover, these needs should not be distilled from current regulatory practice, as it is largely animal-centered. It should begin with the question which parts of human biology needs to be covered in test systems in order to be able to sufficiently detect all toxicities. Downstream follows the design of testing strategies and the selection of a series of appropriate complementary assays for critical key events covering the network of toxicity pathways. This top-down approach is needed to convince scientists and regulators that the necessary biology is comprehensively incorporated into the novel animal-free system. Current activities to design ontology-driven computational systems toxicology approaches as well as IATA and DA show practical applications of this principle. Validation of these integrated approaches in terms of predictability is needed at the level of the strategy, and not at the level of the individual assay. In that respect, it is often considered that case studies at the level of the strategy are the new validation. At the same time the bottom-up aspect remains important, as definition of biological and chemical space and technical validation (e.g. reproducibility and transferability) of individual assays is crucial for determining the usefulness and positioning of individual assays within a testing strategy.

The biology-driven testing-strategy-focused approach of developing alternative approaches towards human chemical hazard and risk assessment is still rather revolutionary. It does not build on current regulatory requirements but starts from the question of the biology that needs to be covered. This naturally meets with reservations from various stakeholders in the current regulatory arena. In the present workshop, experts from a variety of stakeholders including academia, industry, non-governmental organizations and regulatory agencies discussed this innovative approach with an open mind. An open mindset of all stakeholders and active communication between developers and regulators throughout the process are prerequisites for providing a fundament for a transition towards human chemical safety assessment that is mechanistically driven and that avoids the detour of the animal experiment. If anything, this workshop has proven an animated multi-stakeholder podium for developing and sharing ideas supporting novel avenues for chemical risk assessment for man. The challenge lies in keeping the momentum going, and to uphold the necessary pace in scientific progress to provide continuous justification for the optimism as regards the feasibility of these approaches.
Acknowledgments

The authors would like to acknowledge the contributions of the remaining workshop participants: J. Coenen (SET), S. Escher (ITEM), N. Gellatly (NC3Rs), A. Gourmelon (OECD), M. Hermann (Henkel/IKW), M. Herzler (BfR), T. Höfer (BfR), M. Peiser (BfR), D. Petersohn (Henkel), J. Scheel (Beiersdorf), G. Schönfelder (BfR), M. Timmermann (Science Europe), T. Tralau (BfR).
Figure 1. Example of individual versus combined performance of two tests, showing enhanced sensitivity and reduced specificity of the combination as compared to individual tests.
Figure 2. Requisites and prerequisites ("hurdles") of regulatory use of alternative methods (and animal methods alike) (Figure adapted from Landsiedel 2012).
ANNEX I: OECD Test Guidelines Development Flow Diagram

LEGEND
- Profile view
- Normal process

(figure 3 legend on next page)

Figure 4 – Generic elements of Integrated Approaches to Testing and Assessment (IATA) and the role of Defined Approaches (DAs) within IATA. DAs standardise the way in which non-animal/mechanistic data are combined to generate outputs comparable to standard in vivo Test Guidelines.
References


3. OECD. NEW GUIDANCE DOCUMENT ON AN INTEGRATED APPROACH ON TESTING AND ASSESSMENT (IATA) FOR SKIN CORROSION AND IRRITATION. OECD Series on Testing and Assessment. 2014(No.203).


9. OECD. OECD Test guidelines for the testing of chemicals. Section 4: health effects, TG 442D In Vitro Skin Sensitisation: ARE-Nrf2 Luciferase Test Method. 2015.


13. OECD. GUIDANCE DOCUMENT FOR THE USE OF ADVERSE OUTCOME PATHWAYS IN DEVELOPING INTEGRATED APPROACHES TO TESTING AND ASSESSMENT (IATA) Series on Testing & Assessment 2016;No. 260

14. OECD. GUIDANCE DOCUMENT ON THE REPORTING OF DEFINED APPROACHES AND INDIVIDUAL INFORMATION SOURCES TO BE USED WITHIN INTEGRATED APPROACHES TO TESTING AND ASSESSMENT (IATA) FOR SKIN SENSITISATION Series on Testing & Assessment 2016;No. 256.


30. OECD. Test No. 439: In Vitro Skin Irritation - Reconstructed Human Epidermis Test Method. 2015.
32. OECD. OECD test guideline no. 429 Skin Sensitization: Local Lymph Node Assay. OECD SERIES ON TESTING AND ASSESSMENT. 2010.
33. OECD. OECD test guideline no. 442A. Skin Sensitization: Local Lymph Node Assay: DA OECD SERIES ON TESTING AND ASSESSMENT. 2010.
34. OECD. OECD test guideline no. 442B. Skin Sensitization: Local Lymph Node Assay: BrdU-ELISA OECD SERIES ON TESTING AND ASSESSMENT. 2010.


63. OECD. Reconstructed human Cornea-like Epithelium (RhCE) test method for identifying chemicals not requiring classification and labelling for eye irritation or serious eye damage. OECD Guideline for the Testing of Chemicals No. 492. 2017.
64. OECD. In Vitro Skin Sensitisation: ARE-Nrf2 Luciferase Test Method. OECD Guideline for the Testing of Chemicals No. 442D. 2015.
69. OECD. GUIDANCE DOCUMENT ON THE REPORTING OF DEFINED APPROACHES TO BE USED WITHIN INTEGRATED APPROACHES TO TESTING AND ASSESSMENT Series on Testing & Assessment 2016; No. 255.
70. OECD. Guidance Document on the Reporting of Defined Approaches and Individual Information Sources to be Used Within Integrated Approaches to Testing and Assessment (IATA) for Skin Sensitisation. Series on Testing and Assessment No. 256. 2016.